The Latest Breaking News from Blueprint

David Mellen said advice has recently been received on the position of council members on company boards

Why would a 45-year-old father-of-three want to be 18 again? Chelsea Ritschel speaks to Bryan Johnson about his controversial quest to find the fountain of youth

Democratic gubernatorial candidate Wes Moore has proposed a one-year public service option for young Marylanders who graduate from high school without a plan for college or the skills they need for a good job. His proposal for a “service year option” came up during a recent wide-ranging interview at The…

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

Blueprint unveiled the "long-awaited" results of its study in indolent systemic mastocytosis on Wednesday, and the biotech stock crashed.

'There isn’t another project like it in the city'

Sneed: Bolstered by polling, former governor supported mayor last time

It covers a huge area

The FDA recommended Blueprint Medicines change the ultimate goal of a midstage study, leading BPMC stock to crumble Thursday.